Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 199

Similar articles for PubMed (Select 17312304)

1.

Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.

Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A; International Breast Cancer Intervention Study I Investigators.

J Natl Cancer Inst. 2007 Feb 21;99(4):272-82.

2.

Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.

Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M.

J Natl Cancer Inst. 2007 Feb 21;99(4):283-90.

3.

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N.

J Natl Cancer Inst. 2005 Nov 16;97(22):1652-62.

4.

Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women.

Veronesi U, Maisonneuve P, Rotmensz N, Costa A, Sacchini V, Travaglini R, D'Aiuto G, Lovison F, Gucciardo G, Muraca MG, Pizzichetta MA, Conforti S, Decensi A, Robertson C, Boyle P; Italian Tamoxifen Study Group.

J Natl Cancer Inst. 2003 Jan 15;95(2):160-5.

5.

First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial.

Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, Hamed A, Howell A, Powles T; IBIS investigators.

Lancet. 2002 Sep 14;360(9336):817-24.

PMID:
12243915
6.

Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer.

Dignam JJ, Wieand K, Johnson KA, Fisher B, Xu L, Mamounas EP.

J Natl Cancer Inst. 2003 Oct 1;95(19):1467-76.

7.

Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial.

Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, Forbes JF; IBIS-I Investigators.

Lancet Oncol. 2015 Jan;16(1):67-75. doi: 10.1016/S1470-2045(14)71171-4. Epub 2014 Dec 11.

8.

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N.

J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88.

9.

Tamoxifen: an enduring star.

Veronesi U, Maisonneuve P, Decensi A.

J Natl Cancer Inst. 2007 Feb 21;99(4):258-60. No abstract available.

10.

Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy.

Veronesi U, Maisonneuve P, Rotmensz N, Bonanni B, Boyle P, Viale G, Costa A, Sacchini V, Travaglini R, D'Aiuto G, Oliviero P, Lovison F, Gucciardo G, del Turco MR, Muraca MG, Pizzichetta MA, Conforti S, Decensi A; Italian Tamoxifen Study Group.

J Natl Cancer Inst. 2007 May 2;99(9):727-37.

11.

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.

Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM, Deschênes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson AH, Feldman MI, Farrar W, Evans J, Lickley HL.

J Natl Cancer Inst. 1996 Nov 6;88(21):1529-42.

12.

Tamoxifen therapy for breast cancer and endometrial cancer risk.

Bernstein L, Deapen D, Cerhan JR, Schwartz SM, Liff J, McGann-Maloney E, Perlman JA, Ford L.

J Natl Cancer Inst. 1999 Oct 6;91(19):1654-62.

13.

Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study.

Swerdlow AJ, Jones ME; British Tamoxifen Second Cancer Study Group.

J Natl Cancer Inst. 2005 Mar 2;97(5):375-84.

14.

Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).

Beattie MS, Costantino JP, Cummings SR, Wickerham DL, Vogel VG, Dowsett M, Folkerd EJ, Willett WC, Wolmark N, Hankinson SE.

J Natl Cancer Inst. 2006 Jan 18;98(2):110-5.

15.

Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer.

Swain SM, Wilson JW, Mamounas EP, Bryant J, Wickerham DL, Fisher B, Paik S, Wolmark N.

J Natl Cancer Inst. 2004 Apr 7;96(7):516-23.

16.

Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM.

J Natl Cancer Inst. 1994 Apr 6;86(7):527-37.

PMID:
8133536
17.

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group.

Lancet. 2013 Mar 9;381(9869):805-16. Erratum in: Lancet. 2013 Mar 9;381(9869):804.

18.

Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review.

Iqbal J, Ginsburg OM, Wijeratne TD, Howell A, Evans G, Sestak I, Narod SA.

Cancer Treat Rev. 2012 Jun;38(4):318-28. doi: 10.1016/j.ctrv.2011.06.009. Epub 2011 Jul 19. Review.

PMID:
21775065
19.

The nature of tamoxifen action in the control of female breast cancer.

Kodama M, Kodama T.

In Vivo. 2001 Jul-Aug;15(4):319-25. Review.

PMID:
11695224
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk